Trials / Completed
CompletedNCT00394173
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of DNK333 25mg b.i.d. Given Orally for 4 Weeks in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Novartis · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DNK333 | DNK333 25mg b.i.d. given orally for 4 weeks |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-10-31
- Last updated
- 2017-02-27
Locations
43 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00394173. Inclusion in this directory is not an endorsement.